Abstract：
BACKGROUND: At present, the pathogenesis of post-treatment Lyme disease (PTLDS) is not clear, so the treatment scheme of PTLDS, especially antibiotic treatment, is still controversial. This study aims to evaluate the efficacy of antibiotics in the treatment of PTLDS using network meta-analysis (NMA).
METHODS: Following PRISMA guidelines, a systematic literature search was conducted on randomized controlled trials in PubMed, EMBASE, Web of Science and Cochrane Library (the literature was published from database inception through December 16, 2022). Using random effect model and fixed effect model. STATA17.0 software was used to evaluate the quality and heterogeneity of the included research literature.
RESULTS: The system included 4 randomized controlled trials (485 subjects). The network meta-analysis showed that ceftriaxone had better results than placebo [Mean = 0.87, 95% CI (0.02, 1.71)] and doxycycline [Mean = 1.01, 95% CI (0.03, 1.98)] in FSS scale scores. There was no statistical difference in FSS scale scores of other drugs after treatment. In terms of FSS score results, Ceftriaxone was the best intervention according to the SUCRA value of each treatment (97.7). The analysis of outcome indicators such as Beck Depression Inventory (BDI), Mental-health Scale and Physical-functioning scale showed that there was no statistically significant difference between the antibiotic group and placebo group.
CONCLUSIONS: Ceftriaxone treatment may be the best choice for antibiotic treatment of PTLD, which provides useful guidance for antibiotic treatment of PTLD in the future.
METHODS: Following PRISMA guidelines, a systematic literature search was conducted on randomized controlled trials in PubMed, EMBASE, Web of Science and Cochrane Library (the literature was published from database inception through December 16, 2022). Using random effect model and fixed effect model. STATA17.0 software was used to evaluate the quality and heterogeneity of the included research literature.
RESULTS: The system included 4 randomized controlled trials (485 subjects). The network meta-analysis showed that ceftriaxone had better results than placebo [Mean = 0.87, 95% CI (0.02, 1.71)] and doxycycline [Mean = 1.01, 95% CI (0.03, 1.98)] in FSS scale scores. There was no statistical difference in FSS scale scores of other drugs after treatment. In terms of FSS score results, Ceftriaxone was the best intervention according to the SUCRA value of each treatment (97.7). The analysis of outcome indicators such as Beck Depression Inventory (BDI), Mental-health Scale and Physical-functioning scale showed that there was no statistically significant difference between the antibiotic group and placebo group.
CONCLUSIONS: Ceftriaxone treatment may be the best choice for antibiotic treatment of PTLD, which provides useful guidance for antibiotic treatment of PTLD in the future.
摘要：
背景：目前，治疗后莱姆病（PTLDS）的发病机制尚不清楚，所以PTLDS的治疗方案,尤其是抗生素治疗，仍然有争议。本研究旨在使用网络荟萃分析（NMA）评估抗生素在PTLDS治疗中的疗效。
方法：遵循PRISMA指南，对PubMed的随机对照试验进行了系统的文献检索，EMBASE,WebofScience和Cochrane图书馆（文献从数据库开始到2022年12月16日）。采用随机效应模型和固定效应模型。采用STATA17.0软件评价纳入研究文献的质量和异质性。
结果：该系统包括4项随机对照试验（485名受试者）。网络荟萃分析显示，头孢曲松在FSS量表评分中的效果优于安慰剂[Mean=0.87，95％CI（0.02，1.71）]和多西环素[Mean=1.01，95％CI（0.03，1.98）]。其他药物治疗后FSS量表评分无统计学差异。就FSS评分结果而言，根据每种治疗的SUCRA值（97.7），头孢曲松是最佳干预措施。贝克抑郁量表(BDI)等结果指标的分析，心理健康量表和身体功能量表显示，抗生素组和安慰剂组之间没有统计学上的显着差异。
结论：头孢曲松治疗可能是抗生素治疗PTLD的最佳选择，为未来PTLD的抗生素治疗提供了有益的指导。
方法：遵循PRISMA指南，对PubMed的随机对照试验进行了系统的文献检索，EMBASE,WebofScience和Cochrane图书馆（文献从数据库开始到2022年12月16日）。采用随机效应模型和固定效应模型。采用STATA17.0软件评价纳入研究文献的质量和异质性。
结果：该系统包括4项随机对照试验（485名受试者）。网络荟萃分析显示，头孢曲松在FSS量表评分中的效果优于安慰剂[Mean=0.87，95％CI（0.02，1.71）]和多西环素[Mean=1.01，95％CI（0.03，1.98）]。其他药物治疗后FSS量表评分无统计学差异。就FSS评分结果而言，根据每种治疗的SUCRA值（97.7），头孢曲松是最佳干预措施。贝克抑郁量表(BDI)等结果指标的分析，心理健康量表和身体功能量表显示，抗生素组和安慰剂组之间没有统计学上的显着差异。
结论：头孢曲松治疗可能是抗生素治疗PTLD的最佳选择，为未来PTLD的抗生素治疗提供了有益的指导。
